Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.

[Society for Immunotherapy of Cancer @sitcancer]

Register for our 41st Annual Meeting and Pre-Conference Programs. #SITC26 provides a multidisciplinary educational & interactive environment focused on improving outcomes for cancer patients. Attend in person or virtually: https://t.co/R8MURQp83R

[Society for Immunotherapy of Cancer @sitcancer]

One week to go! Join SITC on Oct. 1 for “Precision Immune Oncology,” part of the Computational Immuno-Oncology Webinar Series. Explore emerging approaches shaping the future of cancer immunotherapy. Register today! https://t.co/hZ2FCezItx

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer" https://t.co/f0FtfXzu47

[Chrystal Paulos @Chrystal_Paulos]

New search! 🚨 Tenure-track Asst/Assoc Prof in Cancer Immunology via the M&I Department at @EmoryMedicine + @WinshipAtEmory. Any area of cancer immunology welcome. Bring your best science. CV + 2-pg statement + 3 letters to [email protected] by Nov 6. #CancerImmunology

[Society for Immunotherapy of Cancer @sitcancer]

Now available in @JITC: the updated @sitcancer acute leukemia CPG. Developed by a multidisciplinary panel of experts, this updated guideline offers evidence-based recommendations to help inform immunotherapy treatment decisions for acute leukemia. https://t.co/o9bvEiqkRs

[OncoDaily Biotech @OncoDailyBio]

SITC - Abstract Submissions are Open for the 2027 Spring Scientific Program

@sitcancer

https://t.co/hxLnj2fAeI

[Félix Pastor @felix4better]

Great science is the easy part. Funding and partnerships are what kill most biotech startups. That's the part I'd tune in for on Nov 5.

[Society for Immunotherapy of Cancer @sitcancer]

Thanks for the repost @OncoDailyBio! https://t.co/eCIfjwijdj

[OncoDaily Biotech @OncoDailyBio]

SITC - Abstract Submissions are Open for the 2027 Spring Scientific Program

@sitcancer

https://t.co/hxLnj2fAeI

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

👉

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy" https://t.co/WDrtGGCe3Y

[Society for Immunotherapy of Cancer @sitcancer]

Building a successful biotech startup takes more than great science. Explore the business strategies behind funding, pitching and partnerships at this #SITC26 Pre-Conference Program. Register today and take your biotech venture to the next level! https://t.co/HvrbuEbMX0

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "IgM promotes antitumor immunity to a Tn-expressing solid tumor" https://t.co/C4cOAqppGi

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma" https://t.co/z3Jsl5EOyo

[OncoDaily @oncodaily]

SITC26 Explores the Determinants of Immunotherapy Response

@sitcancer

https://t.co/xgBxyxsEe3

[Society for Immunotherapy of Cancer @sitcancer]

Abstract submissions are open for the 2027 Spring Scientific program. Don't miss the opportunity to explore this year's topic- Breaking New Ground in Cancer Immunotherapy: Cell Therapies, T-Cell Engagers, and Novel IO Strategies. Register today: https://t.co/eCIfjwhLnL

[Society for Immunotherapy of Cancer @sitcancer]

Join Session 203: Hot Topic Symposium at #SITC26 to explore emerging insights into the factors influencing treatment response and what they could mean for the future of cancer immunotherapy. Register today: https://t.co/ZMSOGm1HcI

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study" https://t.co/YtCODIZXF5

[Society for Immunotherapy of Cancer @sitcancer]

Start SITC 2026 with an in-depth look at the latest advances in cancer immunotherapy. Don’t miss this Pre-Conference Program designed to bring together experts, insights and opportunities for scientific exchange on the next gen IO pipeline strategy. https://t.co/R8MURQp83R

[Society for Immunotherapy of Cancer @sitcancer]

Last chance to be this year’s Top Referrer! If you know someone who could benefit from a SITC membership, refer them to join using the Connect-a-Colleague tool. https://t.co/nGw2z0JYYc

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype" https://t.co/7sDgWKr2i0

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance" https://t.co/IxSi5VUp23